Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 10/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 10/20 | 0.49 |
| ▸ | RPA1 | P27694 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MARS1 | P56192 | 3/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.43 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3099863 | 0.84 | RPA1 (0.65) | RPA1MEN1MAPTKMT2AMARS1 | |
| SCHEMBL3092493 | 0.84 | FAAH (0.53) | FAAHGABRA2GABRB2RPA1KDM4E | |
| SCHEMBL3096383 | 0.82 | KDM4E (0.52) | GABRA2GABRB2KDM4EMEN1MAPT | |
| SCHEMBL923028 | 0.82 | RPA1 (0.68) | FAAHGABRA2GABRB2RPA1MEN1 | |
| SCHEMBL3083040 | 0.81 | KDM4E (0.56) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL340947 | 0.80 | GABRA2 (0.59) | FAAHGABRA2GABRB2KDM4EMEN1 | |
| SCHEMBL29419139 | 0.80 | GABRA2 (0.59) | FAAHGABRA2GABRB2KDM4EMEN1 | |
| SCHEMBL342100 | 0.80 | MARS1 (0.68) | FAAHGABRA2GABRB2RPA1MARS1 | |
| SCHEMBL29419099 | 0.80 | MARS1 (0.68) | FAAHGABRA2GABRB2RPA1MARS1 | |
| SCHEMBL3100163 | 0.80 | FAAH (0.50) | FAAHGABRA2GABRB2RPA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803799-B2 | such as 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-5-(selenophen-2-yl)-1H-pyrazole-3-carboxamide, used for treating cannabinoid-receptor mediated disorders selected from obesity, metabolic syndrome, drug abuse and dependence or neuropathic pain | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-09-28 | — | — | US | disclosed |
| US-20080021031-A1 | SELENOPHENE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021031-A1 | SELENOPHENE COMPOUNDS | CNR2, CNR1, SELENOI | FAAH 17/4885GABRA2 200/4885GABRB2 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.